TuHURA Biosciences, Inc./NV
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three months ended March 31, 2025, we received proceeds of $0.5 million for the issuance of 125,201 shares of common stock for warrants exercised. Additionally, we issued a promissory note in the amount of $3.0 million for 1,034,836 shares of common stock for warrants exercised. Each of the common stock purchases for warrants exercised was by an “accredited investor” for the purposes of Rule 501 of Regulation D.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.